Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.42 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22386371 | 1.00 | MEN1 (0.65) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL29462301 | 0.79 | MEN1 (1.00) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL12671882 | 0.74 | MEN1 (0.82) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL17309369 | 0.70 | ITGB3 (0.59) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL17309399 | 0.70 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL19481518 | 0.67 | ITGB3 (0.61) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL17309397 | 0.67 | ITGB3 (0.61) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL3364192 | 0.64 | CFTR (1.00) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL3364187 | 0.64 | CFTR (1.00) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL17309389 | 0.62 | CA9 (0.56) | MEN1KMT2AALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148541-B1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIV BERN (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10300048-B2 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | UNIVERSITAT BERN (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-10-19 | — | — | US | disclosed |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-10-19 | — | — | US | disclosed |
| EP-2952188-A1 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | Universität Bern (CH) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015181336-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | Universität Bern (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300048-B2 | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | SLC18A2, AANAT, CNR2 | MEN1 4253/4885KMT2A 2455/4885ALDH1A1 395/4885 |
| US-20170296515-A1 | THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | SLC18A2, AANAT, CNR2 | MEN1 4253/4885KMT2A 2455/4885ALDH1A1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.